The Arctic Alzheimer mutation favors intracellular amyloid‐β production by making amyloid precursor protein less available to α‐secretase
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Mutations within the amyloid‐β (Aβ) domain of the amyloid precursor protein (APP) typically generate hemorrhagic strokes and vascular amyloid angiopathy. In contrast, the Arctic mutation (APP E693G) results in Alzheimer’s disease. Little is known about the pathologic mechanisms that result from the Arctic mutation, although increased formation of Aβ protofibrils in vitro and intraneuronal Aβ aggregates in vivo suggest that early steps in the amyloidogenic pathway are facilitated. Here we show that the Arctic mutation favors proamyloidogenic APP processing by increased β‐secretase cleavage, as demonstrated by altered levels of N‐ and C‐terminal APP fragments. Although the Arctic mutation is located close to the α‐secretase site, APP harboring the Arctic mutation is not an inferior substrate to a disintegrin and metalloprotease‐10, a major α‐secretase. Instead, the localization of Arctic APP is altered, with reduced levels at the cell surface making Arctic APP less available for α‐secretase cleavage. As a result, the extent and subcellular location of Aβ formation is changed, as revealed by increased Aβ levels, especially at intracellular locations. Our findings suggest that the unique clinical symptomatology and neuropathology associated with the Arctic mutation, but not with other intra‐Aβ mutations, could relate to altered APP processing with increased steady‐state levels of Arctic Aβ, particularly at intracellular locations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“These mutations were later shown to alter APP processing leading to either increased production of Ab in general (the Swedish mutation) or shifting production toward Ab42 (the London mutation) (Citron et al. 1992; Suzuki et al. 1994).”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 2×
“The Swedish (Mullan et al. 1992) and London (Goate et al. 1991) APP mutations, which frame the Ab domain, were the first to be associated with AD.”
BackgroundSelf-citationSuzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“The discoveries of mutations in amyloid precursor protein (APP), presenilin-1 and presenilin-2, causing early-onset AD, and the realization that these mutations all lead to increased Ab42 levels has created an immense interest in APP processing (Hardy 1997; Selkoe 1998; Wilson et al. 1999).”
BackgroundThe 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 7×
“1999), Arctic (Nilsberth et al. 2001) and Iowa (Grabowski et al.”
BackgroundResultInfluentialSelf-citationAph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · cited 1×
“Levels of cell surface APP were also analyzed in cells with only the Arctic mutation (APPArc), as it is known that APP with the Swedish mutation is present in higher degree within the trans-Golgi network (Haass et al. 1995).”
BackgroundSelf-citationGrabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523 · cited 2×
“Several pathogenic APP mutations inside the Ab domain, close to the a-secretase cleavage site, have been identified, e.g. the Flemish (Hendriks et al. 1992), Dutch (Van Broeckhoven et al. 1990), Italian (Tagliavini et al. 1999), Arctic (Nilsberth et al. 2001) and Iowa (Grabowski et al. 2001) mutations.”
BackgroundNäslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468 · cited 5×
“The discoveries of mutations in amyloid precursor protein (APP), presenilin-1 and presenilin-2, causing early-onset AD, and the realization that these mutations all lead to increased Ab42 levels has created an immense interest in APP processing (Hardy 1997; Selkoe 1998; Wilson et al. 1999).”
BackgroundInfluentialSelf-citationSelkoe (1999) · doi:10.1038/19866 · Cited by 468
Cited by
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citationTargeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Mutant A53T α-Synuclein Induces Neuronal Death by Increasing Mitochondrial Autophagy
Choubey, V., Safiulina, D., Vaarmann, A., Cagalinec, M., Wareski, P., Kuum, M., Zharkovsky, A., & Kaasik, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132514 · Cited by 262
Nilsson, K. P. R., Åslund, A., Berg, I., Nyström, S., Konradsson, P., Herland, A., Inganäs, O., Stabo-Eeg, F., Lindgren, M., Westermark, G. T., et al. (2007) · ACS Chemical Biology · doi:10.1021/cb700116u · Cited by 190
Self-citationAlzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
“This 016). rate of formation of PFs (Johansson et al., 2006; Nilsberth et al., 2001; Sahlin et al., 2007).”
Nishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M. P., Klein, W. L., & Mori, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080480 · Cited by 127
“The increased production and intracellular accumulation of A have also been demonstrated in another APP mutation, the Arctic (E693G) mutation.(29) This mutation decreases cell surface expression of APP by reduced trafficking to the plasma membrane and/or increased endocytosis of APP and thereby reduces availability fo…”
BackgroundInsights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114
Istradefylline reduces memory deficits in aging mice with amyloid pathology
Orr, A. G., Lo, I., Schumacher, H., Ho, K., Gill, M., Guo, W., Kim, D. H., Knox, A., Saito, T., Saido, T. C., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.014 · Cited by 87
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Metadata
- Authors
- Sahlin, C., Lord, A., Magnusson, K., Englund, H., Almeida, C. G., Greengard, P., Nyberg, F., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-11
- Volume
- 101
- Issue
- 3
- Pages
- 854-862
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1553423283
- Cited by
- 62
- References
- 15
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.